Oral contraceptives and mortality from venous thrombosis by Rosendaal, F.R.
VW
, » , , ·. *
^^
THE LANGET
Leiters to the Editor
Oral contraceptives and mortality from ,
venous thromboembolism
SIR—Vandenbroucke and colleagues (Äug 10, p 40l)1 and
Thomas (Äug 10, p 402)2 believe that the modest increase in
mortality from venous thromboembolism (VTE) among
young women that occurred between the mid-1980s and the
early 1990s might have been due to the increased use of oral
contraceptives (OCs) containing one of the newer
progestagens (desogestrel or gestodene). We question their
Interpretation of the fmdings.
Death from VTE accounts for less than 1% of total
mortality in women aged 15-44 years. Moreover, only a few
deaths are not associated with trauma, surgery, or major
illness. It follows that most of the 2-8 deaths per million
women could not be associated with OCs. Because of its
association with other illnesses the apparent frequency of
death from VTE will be affected both by the preference of
doctors (and coroners) when completing death certificates
and by coding practices adopted by national statistical
authorities. Investigators should be cautious in their
Interpretation of both absolute rates and secular trends in
mortality.
Vandenbroucke and co-workers draw conclusions about
the association between OC exposure and VTE from
consideration of the secular trends in the death rates in
15-44 year olds estimated from a maximum of 20 deaths
annually. In this age group about 60% of the VTE deaths will
be in those over age 30, whereas about 70% of OC use is by
women under this age. If any changes in mortality from VTE
had been due to OC use then they would be limited to
women. The Dutch mortality rates indicate that the female
to male ratio feil between 1985 and 1990 and remained
stable thereafter. Thus, if the recent modest rise in female
mortality was caused by changes in the patterns of OC use,
then to explain the proportionately greater rise in males
during the same period we would need to identify an agent
that uniquely affects the male. In England and Wales,
according to Thomas, the ratio between males and females
aged 30-44 remained more or less stable and for neither sex
is there a discernible secular trend. Mortality from VTE in
males aged 15-29 is so low that year by year changes in
female to male mortality cannot be ascertained. There seems
to have been an increase in death rates among 15-29-year-
old women between 1989 and 1990; between 1990 and 1992
rates were stable.
Since all combined OCs carry an increased risk of
thromboembolic disease it is important to establish whether
any trends are associated with overall usage before focusing
on particular products. Between 1984 and 1990 the number
of cycles used in the UK increased by 23·7% (from 31-6 to
39-1 million), and there was a modest increase in mortality
from VTE among-15-29-year-old women (1·6 to 4·4 per
million). Between 1990 and 1992 the number of cycles used
increased by 11-2% (to 43-5 million), and there was no
change in mortality. However, between 1990 and 1993 the
Proportion of OCs used that contained one of the suspect
progestagens increased from 20·!% to 44-0%.* Multiple
linear regression for the death rates amongst 15-29 year olds
against total cycles and the proportion containing the newer
*Tables showing füll data for England and Wales and the Netherlands
are available from The Lancet or the authors, on request
progestagens gives a regression coefficient of 0-87, with an χ
coefficient for total use of +0-59 and that for the proportion
of use of OCs containing newer progestagens of -0-09: the
equivalent figures for 30—44 year olds are 0·15, +0-40, and
—0-13. For the Netherlands, in women aged 15-44, the
regression coefficient is 0-41 with an χ coefficient for total
OC use of 0-39 and that for the proportion containing newer
progestagens being -0-02. Assuming that the principal
determinant of VTE death were OC use diese calculations
indicate that the modest changes in VTE mortality could be
accounted for in part by changes in the overall use of OCs,
but that any such effect was limited by the introduction of
OCs containing newer progestagens. This conclusion is
consistent with the hypothesis that the newer products are
safer than those they replaced.
*Richard Farmer, Michael Lewis
«Department of Public Health and Primary Care, Charing Cross and
Westmmster Medical School, Chelsea and Westminster Hospital,
London SW10 9NH, UK; and Potsdam Institute of Pharmacoepidemiology and
Technology Assessment, Associated Institute of Potsdam University, Potsdam,
Germany
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SIR—The debate on the safety of OCs is further confused by
Vandenbroucke' and colleagues1 and Thomas'2 reports on
mortality rates from VTE in the Netherlands and the UK.
These investigators believe that their data support a
hypothesis that third-generation OCs are associated with an
increased frequency of VTE. Such a consideration would be
relevant if bias could be excluded. Recent work indicates,
however, the existence of biases,'·4 and suggests that earlier
epidemiological studies were not able to adequately adjust for
these biases. One of the initial studies5 also assessed mortality
from cardiovascular disease and found no difference between
users of preparations with second-generation and third-
generation progestagens; this is not surprising because the
frequency of VTE morbidity in OC users in that study was
not higher than that of 15 years ago.
The data on which Vandenbroucke and colleagues base their
conclusion fail to indicate any rise in mortality in the female
group that was not present in the male group. Vandenbroucke
is worried about the mortality rate in Dutch women during
1993 and 1994 compared with the end of the 1980s but does
not comment on the unchanged female to male ratio in that
period (1988, 2-1; 1989, 2-6; 1994, 1-9*). If anything, this
ratio indicates a slight decrease in VTE mortality in women
relative to men, which contradicts any concern over VTE in
women using third-generation OCs. Moreover, the sudden
increase in VTE mortality in 1993 and 1994 is unlikely to be
related to the increasing use of third-generation OCs because
changes in OC use in the Netherlands occurred much earlier.
Third-generation pills were introduced in the early 1980s; by
1987 25% of OC users were taking a third-generation
formulation. Since then there only has been a gradual increase,
to 31-2% in 1991 and 36·8% in 1995 (data from a yearly
population-based survey, unpublished). The data from
Thomas provide merely erratic shifts in the female to male
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ratio and thus do not allow any Interpretation.
The absence of a biological explanation of the differential
VTE frequencies, the absence of confirmation by mortality
data, and the increasing evidence of bias in the initial smdies
should end the efforts of scientists trying to revive a pill scare
that should not have occurred in the first place, and that
already has led to increasing unwanted pregnancy and
abortion rates in several European countries.
Rik H W Van Lunsen
Department of Sexology and Psychosomatic Gynaecology, Academic Medical
Centre, University of Amsterdam, 1105AZ Amsterdam, Netherlands
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SIR—The latest eruption of epidemiology into modern
medicine is again unjustifiable and may have negative
consequences. Vandenbroucke and colleagues' and Thomas2
suggest that third-generation OCs increase mortality from
VTE in women—yet another example of disputable effects of
epidemiology. Both groups base their interpretation on a
slight increase in mortality from VTE in women in the past
few years. However, they fail to explain the proportionally
similar trends in men over the same period. In addition, it is
not logical that suggested effects of third-generation OCs are
observed years after (Dutch data) or before (UK data) they
were widely used, whereas OC-associated VTE occurs
mainly in women just starting on OCs;
Vandenbroucke and Thomas' interpretations are even
more surprising since the suggested increase in mortality
from VTE cannot be related to the use of OCs. The
frequency of OC-associated VTE did not increase in the time
of their investigation, äs evident from cohort studies. In the
early 1980s four cases of VTE were recorded in 10000 OC
users3 per year, whereas, at most, three cases of VTE in
10 000 OC users4·5 per year were found in the recent cohort
studies from the early 1990s, when third-generation OCs
were available.
An increasing number of new publications on the OC and
VTE issue point out that the observed difference in
frequency of VTE between OCs of the second and third
generation may result from biases and confounders radier
than a biological effect. As pointed out by Thomas, "death
certificate diagnoses may not be accurate, changes in
mortality with time may reflect changes in other risk factors,
and there may be diagnostic bias".
These considerations re-emphasise the need for critical
evaluation of epidemiological data and their clinical
relevance. Will we ever learn from this and previous pill
scares?
Jean Cohen
International Federation of Fertllity Sooietles, 8 Rue de Marignan, Paris 75008, .
France " " ""' '
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Authors' reply
SIR—Discussion about the time trend in venous
thromboembolism was started to point to a discrepancy:1 it
has been said that no increase had been demonstrated among
young women, whereas an increase would have been
expected if third-generation contraceptives carried twice the
risk. On checking data for two countries, we found increases
in mortality. Whether this is accepted äs further evidence for
the association between venous thrombosis and third-
generation contraceptives depends on one's previous beliefs.
Nevertheless, it becomes difficult to use the mortality data äs
an argument against the epidemiological studies.
Your correspondents propose that the data should be
analysed proportionally, without explaining why rise and fall
of diseases ought to be proportional in men and women. If
proportional, the absolute increase among women remains
larger than among men. The British data reported by
Thomas do not fit the proportionality argument: mortality
from venous thrombosis among young men shows no sign of
change, whereas there is a continuous increase among young
women.
Farmer and Lewis try to solve an equation with too many
unknowns: it is impossible to calculate the relative mortality
between two subgroups only from total mortality and the
proportions of the subgroups without making an assumption
on mortality in one of the groups. In their regression analysis,
they use two explanatory variables (total use of
contraceptives and percentage of third generation) that are
strongly interdependent (correlations of 0-95 and 0-99),
which leads to unstable estimations. The instability of their
estimates is demonstrated by very large p values (which we
recalculated). Moreover, plotting the data shows that the
increase in the use of third-generation contraceptives strongly
violates the linearity assumption of the regression analysis.
The use of a linearising transformation in the Dutch data
(squaring), clearly improves the fit of the model and the
picture completely reverses: the coefficient of third-
generation use now becomes positive (with a smaller p value)
and that of total use becomes negative. We do not need this
reanalysis to maintain that the mortality data are in line with
the epidemiological studies.
We are amazed by the continuing insistence that bias and
confounding explain the epidemiological studies. The Starter
bias argument is answered by looking separately at first-time
users in the WHO, the Transnational, and the UK-General
Practice Research Database (GPRD) study, and during the
first year of use in a reanalysis of the WHO study.2 The
referral bias argument is answered by the observation that
certainty of diagnosis did not influence the results in the
WHO and the UK-GPRD study. The prescribing bias
argument is answered by the observation that patients with
major underlying disease were excluded (so that most cases .,
are either idiopathic or linked to unpredictable intercurrent; -"V,
events like trauma or immobilisation), and by the adjustment ~· '= ·* ;
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for the important long-term risk factors for venous
thrombosis. v
 t 1 *, ,
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A uthör's reply
SIR—Mortality statistics have limitations, äs I stated in my
letter, but Farmer and Lewis are wrong to suggest that most
of these thromboembolism deaths are likely to relate to
trauma or serious medical illnesses. In such cases the
underlying ilhiess (not the terminal thromboembolism) was
coded äs the cause of death throughout the study. Some
misdiagnosis or miscoding might have occurred, but one
would expect most young women dying from idiopathic
thromboembolism to have the diagnosis established by a
coroner's necropsy unless it was already apparent from
antemortem investigations.
Farmer and Lewis suggest that increases in mortality may
relate to increases in overall consumption of oral
contraceptives during the period. The source of their pill-use
data is not defined, it does not refer to the same geographic
area, and it is not age specific. At least some of the increase in
use will relate to women aged over 30.' Their multiple
regression analysis is flawed because the two χ variables they
use (total utilisation and proportion of new pills) are not
independent, one being a component of the other: this
produces so-called multicollineanty, with unstable and
unreliable estimates. They fail to mention that the relations
they describe between their utilisation data and the mortality
changes I reported are not statistically significant. To some
extent the shortcomings of their analysis can be overcome by
using utilisation of old (total minus new pills) and new pills
äs separate variables. Interestingly, this analysis reveals a
significant relation between mortality in young women and
use of new (ρ<0·02) but not old (ρ>0·1) preparations.
Inclusion of Farmer and Lewis's utilisation data therefore
Supports the temporal association between uptake of third-
generation products and the increase in mortality.
A more appropriate method is to estimate the expected
increase in mortality from thromboembolism in women aged
15-29 resulting from these changes in use. If the new
products carry the same risk äs older products and an overall
exposure of 37% in 1984 is assumed, the expected rise in
mortality due to increased use between 1984 and 1992
would be 12%, which is much smaller than the observed
increase. If new preparations carry double the risk (äs
estimated in the epidemiological studies) the expected
increase in mortality would be 44%, which is lower than the
observed mortality increase, but within its 95% CL Of
course, larger increases in mortality would occur if there was
selective use of newer preparations in younger women.
Cohen and van Lunsen are unwise to draw conclusions
from the direct comparison of incidence rates from old and
more recent cohort studies. Differences in study methods
(eg, ages studied) and changes in the use of oral
contraception (eg, patient selection and monitoring, reduced
oestrogen doses) will affect the findings. The one study cited
that compared preparations containing different
progestagens showed that those containing levonorgestrel are
now associated with a lower risk than previously, but the risk
is significantly higher ,with preparations containing
• desogestrel or gestodene.* -,·»„·»' -w <f - -,
Your correspondents play down the problem by referring
1
 to the doubling in mortality in young women äs a "slight"ρτ
"modest" increase; van Lunsen refers to an "absence of
confirmation by mortality data". Three separate case-control
studies (including one of which Lewis is a co-author3) and a
cohort study indicate an increased risk of thromboembolism
with preparations containing desogestrel or gestodene. Since
their introduction mortality from this cause has increased in
younger women. I believe this is ample justification for the
concern I expressed previously.
SHL Thomas
Wolfson Unit of Clinical Pharmacology, Department of Pharmacological Sciences,
University of Newcastle, Newcastle upon Tyne NE2 4HH, UK
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Coordination of Poliomyelitis immunisation
Programme in China's border areas
Sm—Since the World Health Organization adopted a goal to
eradicate poliomyelitis by the year 2000, the number of
reported cases has gradually decreased. Well-organised AFP
(acute flaccid paralysis) surveillance Systems with laboratory
networks and supplementary immunisation programmes,
including national immunisation days, designed to promote
oral poliovirus vaccine (OPV) immunisation, have greatly
contributed to this decrease.1"3
Of the four wild poliovirus strains isolated in China
between 1995 and April, 1996, all occurred in Yunnan
Province, in four children with paralytic polio. They lived in
Myanmar and were seen at the De Hong Prefectural Hospital
(table). Isolates were confirmed äs wild strains by the PCR-
RFLP.4 Yunnan Province, which is in southwestern China,
shares 4060 km of its border with Myanmar, Laos, and
Vietnam.
Three national immunisation days were held in China
between 1993 and 1996, with more than 90% coverage
reported. Myanmar conducted its first such Programme in
February and March of 1996. Despite these efforts, the
border areas remained susceptible to outbreaks of polio.
These areas have transient populations that often move
across the border. The four patients who were paralysed
came to China to see the doctor, although they were
residente of Myanmar. Investigations at nine hospitals in De
Hong Prefecture revealed that they provided medical Services
to 22062 patients from Myanmar in 1995.
Even though races, culture, and languages are fairly
uniform in these areas, it is difficult for health authorities to
Gase
1
2
3
4
Age
1 yr 4 mo
1 yr 11 mo
3 yr 11 mo
2 yr 0 mo
Resldence
Myanmar
Myanmar
Myanmar
Myanmar
OPV
hlstory
None
None
None
None
Paralysis onset
Nov 8, 1995
Feb 24, 1996
Mär 11, 1996
Apr 1, 1996
Poliovirus
Isolated
Type 1, wild
Type 1, wild
Type III, wild
Type III, wild
OPV=oral polio vaccine.
Table: Four patients from whom wild polioviruses were Isolated
In China (Jan, 1995-Aug, 1996)
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